CL
JUNO

CPWM LLC’s Juno Therapeutics, Inc. JUNO Stock Holding History

CPWM LLC’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-5,566
Closed -$214K – 281
2016
Q2 		$214K Hold
5,566
– – 0.05% 246
2016
Q1 		$212K Buy
+5,566
New +$194K 0.05% 249

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

CPWM LLC's JUNO Position: Q3 2016 in Review

CPWM LLC sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2016, closing a stake of 5,566 shares — an estimated $214K sold.

CPWM LLC first reported a position in JUNO in Q1 2016 and held it in 2 quarters. The position peaked at $214K in Q2 2016. 169 funds tracked by Wall St. Rank hold JUNO as of Q3 2016.

  • CPWM LLC reported no remaining Juno Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • CPWM LLC sold 5,566 Juno Therapeutics, Inc. shares in Q3 2016, an estimated $214K.
  • CPWM LLC first reported a position in Juno Therapeutics, Inc. in Q1 2016 and held it in 2 quarters.
  • CPWM LLC's Juno Therapeutics, Inc. position peaked at $214K in Q2 2016.
  • 169 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2016.

Based on CPWM LLC's 13F filing for Q3 2016, filed 9 Jun 2017.